FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

Related Keywords

Japan ,Switzerland ,United Kingdom ,Israel ,Great Britain ,Bryan Campbell ,Bristol Myers Squibb ,Al Olaa Abdallah ,Us Myeloma Innovations Research Collaborative ,University Of Kansas ,European Union ,Cell Therapy ,Safety Study ,Standard Regimens ,Subjects With Relapsed ,Refractory Multiple Myeloma ,Clinical Associate Professor ,Clinical Director ,Hematologic Malignancies ,Cellular Therapeutics ,Innovations Research ,